Latigo Swaps CEO Two Months After IPO; Todd Smith Takes Over From Nima Farzan
LTGO is trading near its 52-week low of $13.26 (6.8% above the low).
Summary
Latigo replaced CEO Nima Farzan with Todd Smith effective November 3, 2026, two months after its IPO, and reported Q3 cash of $401.2 million that funds operations into 2029. Both lead programs are guided to topline data in the second half of 2027.
Key Events · Executive and Board Changes · LTGO
-
CEO Replaced Two Months After IPO
Todd Smith became President and CEO effective November 3, 2026, replacing Nima Farzan, who also resigned from the board. The company said the resignation was not due to any disagreement.
-
New CEO's Pay Package
Smith receives a $775,000 base salary, a 70% target cash bonus and an option award with a $20,000,000 grant-date fair value, vesting 25% after one year and the rest monthly over 36 months.
-
Farzan Stays On as Consultant
Farzan remains an employee through January 1, 2027 at current compensation, then a consultant through December 31, 2027, continuing to vest equity; he also gets his 2026 bonus at 100% of target.
-
Cash Funds Operations Into 2029
Cash and equivalents were $401.2 million at September 30, 2026. Q3 R&D was $17.5 million, G&A $5.4 million and net loss $20.9 million, versus a $24.8 million loss a year earlier.
Analysis · LTGO · Life Sciences
The headline is a CEO change this soon after an August IPO: the board replaced Nima Farzan with Todd Smith effective November 3, 2026, and Farzan has left the board. The company says the departure was not over a disagreement, and Farzan stays on payroll through January 1, 2027 and as a consultant through December 31, 2027, so the transition is orderly rather than a rupture. Smith's package — $775,000 salary, a 70% target bonus and a $20 million grant-date-value option award — is a large equity commitment for a company this size and ties him to the Phase 3 readouts. Against that, the Q3 update shows $401.2 million of cash that funds operations into 2029, so the new CEO inherits a funded runway and two programs (onzotrigine Phase 3 and LTG-321 Phase 2) both guided to topline in the second half of 2027. The quarter itself was unremarkable: net loss narrowed to $20.9 million from $24.8 million a year earlier.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LTGO was trading at $14.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $930.8M. The 52-week trading range was $13.26 to $25.93. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.